Many barriers exist to the translation and implementation of European and US guidelines for cardiovascular disease into clinical practice in China, but also to the development of Chinese-specific guidelines. Professors Zhao and Hu give their expert perspectives on the multifaceted reasons for these barriers, and how future guidelines for Chinese clinical practice should be developed and applied.
